Daniel Lee, MD
Ophthalmology · Princeton, NJNPI 1649566290
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,066 of the $5,212 with a category attached, or 78.0%. 20 manufacturers reported payments, led by Glaukos Corporation at 38.2% of the total. Reporting peaked in 2020 at $1,443 and has fallen 86.0% since, to $202 in 2025.
Across 92 payments — averaging $56.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$954
- Aerie Pharmaceuticals, Inc.$432
- NEW World Medical,inc.$402
- Bausch & Lomb Americas Inc.$240
- Sight Sciences, Inc.$186
- plus $1K from 14 others
Across 17 payments — averaging $3705.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$48K
- Ocular Therapeutix, Inc.$15K
What the payments were for
- Speaking & faculty fees$1,00019%
- Travel & lodging$1463%
- Food & beverage$4,06678%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 16 | $1,993 |
| Alcon | 17 | $954 |
| Aerie Pharmaceuticals, Inc. | 11 | $432 |
| NEW World Medical,inc. | 2 | $402 |
| Bausch & Lomb Americas Inc. | 10 | $240 |
| Sight Sciences, Inc. | 6 | $186 |
| AbbVie(2 entities) | 7 | $150 |
| Astellas Pharma US Inc | 1 | $150 |
| Intuitive Surgical | 1 | $146 |
| Medtronic | 2 | $145 |
| Oyster Point Pharma, Inc. | 6 | $97 |
| Acclarent, Inc | 1 | $90 |
| Genentech USA, Inc. | 3 | $60 |
| Tarsus Pharmaceuticals, Inc. | 3 | $53 |
| Boston Scientific | 1 | $27 |
| Medline Industries LP | 1 | $21 |
| Thea Pharma Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $17 |
| Iridex Corporation | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,212 in reported general payments places this provider in the 80th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 142 | $86,024 |
| CombiganBrimonidine Tartrate/Timolol | 120 | $47,757 |
| RestasisCyclosporine | 30 | $39,875 |
| VyzultaLatanoprostene Bunod | 59 | $31,291 |
| XiidraLifitegrast | 25 | $28,492 |
| RhopressaNetarsudil Mesylate | 40 | $24,858 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 51 | $17,466 |
| Alphagan PBrimonidine Tartrate | 25 | $13,645 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 65 | $11,655 |
| Latanoprost | 854 | $11,415 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $11,036 |
| Travoprost | 64 | $10,143 |
| Brimonidine Tartrate | 201 | $9,951 |
| Timolol Maleate | 246 | $9,746 |
| ProlensaBromfenac Sodium | 28 | $9,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $150 | $187,301317 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $240 | $59,78384 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $432 | $35,89462 claims |
| AlconSimbrinza | $954 | $17,46651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Princeton
- Rahul TonkPrinceton$70K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.